LEADER 01552nam  2200433   450 
001 9910707234603321
005 20160623090144.0
035   $a(CKB)5470000002463164
035   $a(OCoLC)952092169
035   $a(OCoLC)995470000002463164
035   $a(EXLCZ)995470000002463164
100   $a20160623d2005      ua             0
101 0 $aeng
135   $aurmn|||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aHow inflated published prices affect drugs considered for the federal upper limit list
210  1$a[Washington, D.C.] :$cDepartment of Health and Human Services, Office of Inspector General,$d2005.
215   $a1 online resource (iv, 15 pages) $cillustrations
300   $aTitle from title screen (viewed June 22, 2016).
300   $a"September 2005."
300   $a"OEI-03-05-00350."
320   $aIncludes bibliographical references.
517 1 $aHow inflated published prices affect drugs considered for the federal upper limit list
606   $aMedicaid
606   $aDrugs$xPrices$zUnited States
606   $aPharmaceutical services insurance$zUnited States
606   $aPharmaceutical policy$zUnited States
615  0$aMedicaid.
615  0$aDrugs$xPrices
615  0$aPharmaceutical services insurance
615  0$aPharmaceutical policy
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910707234603321
996   $aHow inflated published prices affect drugs considered for the federal upper limit list$93310663
997   $aUNINA